This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Miriam Gross, Lady Owen; literary editor and writer; literary editor of The Observer, arts editor of The Daily Telegraph, literary editor of The Sunday Telegraph, senior editor (and co-founder) of Standpoint; edited Channel Four's Book Choice; at The Observer, she conducted a series of interviews, with, among others, the poet Philip Larkin, playwright Harold Pinter, thriller writer John le Carré, painters Francis Bacon and David Hockney, Nobel Prize-winning Russian poet Joseph Brodsky, novelist Anthony Powell, philosopher and historian Sir Isaiah Berlin, philosopher A.J. Ayer, and Stalin's daughter Svetlana Stalin; has written for the Financial Times; has also served as judge on the Booker prize and on George Orwell memorial prize. Susanna Gross, literary editor of The Mail on Sunday since 1999 and columnist for The Spectator; previously worked as an editor at the Daily Mail, was features editor of Harper's Bazaar, and was deputy editor of The Week; daughter of literary critic and writer John Gross and literary editor Miriam Gross, and the granddaughter of humanitarian Kurt May, she is married to novelist and critic John Preston; brother Tom Gross is a journalist and international affairs commentator, specialising in the Middle East; stepdaughter of Sir Geoffrey Owen.
== Medicinal Use == Traditional Medicine The resin of Croton lechleri, commonly known as sangre de drago, has a long history of medicinal use by indigenous peoples and is widely used in both urban and rural contexts in Peru and Ecuador, and to a lesser extent in other endemic countries.[8] For centuries, the sap has been used to cover abrasions, cuts, scratches, blisters, bites and stings to prevent bleeding, decrease inflammation, seal wounds and injuries to protect from infection. The sap dries quickly on soft, damaged tissue, forming a barrier similar in thickness to the skin removed, noted as something akin to a "second skin." Antimicrobial activity offered by the plant is further believed to offer protection to the injury. The formation of this resistant barrier is likely due to the saps ability to co-precipitate with surrounding proteins or extracellular matrix elements. The hemostatic qualities relevant in wound healing that are associated with sangre de grado are further relevant to Amazonian indigenous communities in arresting the large amounts of bleeding following childbirth. Beyond cutaneous ailments, the use of sangre de grado is taken orally for gastrointestinal disorders and irregularities including gastritis, gastric ulcers, intestinal infections, and inflammation.
=== Mechanical engineer === In 1912, Jones moved to Hallock, Minnesota, where he worked as a mechanic on a 50,000-acre (200 km2) farm. The farm was owned by James J. Hill, who was also owner of the Great Northern Railroad. Jones' proximity to Hill and the railroad facilitated his education in electricity and steam locomotive engines. Jones lived there for more than 20 years and would later say in a newspaper article that Hallock was a place "where a man … [was] judged more on his character and ability than on the color of his skin." He was locally known as "Casey" due to a remark by a railroad engineer he met while working at Hill Farm (see also Casey Jones). Jones received his engineering license at age 20. He later upgraded his license to the highest grade.
Another emerging and promising application of freeze casting is the production of porous foams for green hydrogen generation through advanced thermochemical processes like Chemical Loop Combustion (CLC) and the Steam Iron Process (SIP). These processes leverage the unique properties of porous metal structures, such as optimized reaction kinetics, enhanced thermal efficiency, and sustainability. In Chemical Loop Combustion (CLC), foams made from materials like iron oxides act as oxygen carriers, enabling fuel combustion without direct air contact, separating CO2 for capture while producing high-purity hydrogen. Similarly, in Steam Iron Process (SIP), dendritic pore structures ensure efficient water vapor distribution and maximize hydrogen yield. The precise control over porosity and thermal properties afforded by freeze casting, along with the use of eco-friendly solvents like camphene, positions these foams as a vital innovation for scalable and sustainable hydrogen production, contributing to the fight against climate change.
Sources: en.wikipedia.org
symporter Any of a class of transmembrane transporter proteins which facilitate the transport of two or more different molecules across the membrane at the same time and in the same direction; e.g. glucose and sodium ions. Contrast antiporter and uniporter.
A substrate (quartz, silicon, stainless steel, carbon fibers, etc.) is coated with a catalytic metal (Fe, Co, Ni) layer. Typically that layer is iron and is deposited via sputtering to a thickness of 1–5 nm. A 10–50 nm underlayer of alumina is often also put down on the substrate first. This imparts controllable wetting and good interfacial properties. When the substrate is heated to the growth temperature (~600 to 850 °C), the continuous iron film breaks up into small islands with each island then nucleating a carbon nanotube. The sputtered thickness controls the island size and this in turn determines the nanotube diameter. Thinner iron layers drive down the diameter of the islands and drive down the diameter of the nanotubes grown. The amount of time the metal island can sit at the growth temperature is limited as they are mobile and can merge into larger (but fewer) islands. Annealing at the growth temperature reduces the site density (number of CNT/mm2) while increasing the catalyst diameter. The as-prepared carbon nanotubes always have impurities such as other forms of carbon (amorphous carbon, fullerene, etc.) and non-carbonaceous impurities (metal used for catalyst). These impurities need to be removed to make use of the carbon nanotubes in applications.
=== 27 July === One person was killed by Russian shelling in Sumy Oblast. Ukrainian drones struck the Olenya air base in Murmansk Oblast, some 1,800 kilometers from the Ukrainian border, damaging two Tu-22M3s. Engels and Dyagilevo airfields were also attacked, along with an oil refinery in Ryazan. Russian air defence claimed to have shot down 12 drones over various oblasts. The Ukrainian 79th Air Assault Brigade again claimed to have repulsed a Russian assault east of Kurakhove, killing 23 Russian soldiers and injuring 29, as well as destroying a tank and two AFVs.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.